[{"data":1,"prerenderedAt":175},["ShallowReactive",2],{"drug-betamethasone-valerate":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":36,"contraindications":57,"warnings":67,"renal":75,"monitoring":76,"interactions":77,"review":78,"examples":81,"atc":87,"iran":89,"links":125,"populations":144,"usApproval":170},"betamethasone-valerate",1,{"fa":7,"en":8},"بتامتازون والرات موضعی","Betamethasone valerate (topical)","dermatology",{"fa":11,"en":12},"کورتیکواستروئید موضعی قوی","Potent topical corticosteroid",[14],{"name":15,"market":16},"Betnovate","GB",[18,19,20,21],"betnovate","بتنوویت","بتامتازون","پماد بتامتازون",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":30,"refs":32},"oint-0-1","ointment","topical","0.1% ointment",{"amount":5,"unit":29,"perUnit":29},"application",[31],"US",[33],{"source":34,"section":35},"fda-betamethasone-valerate","How Supplied",[37],{"id":38,"disease":39,"label":40,"population":43,"type":44,"unit":29,"dose":45,"refs":47,"notes":50},"derm","dermatitis",{"fa":41,"en":42},"درماتوز پاسخ‌ده به کورتون — دو بار در روز","Corticosteroid-responsive dermatoses — twice daily",{},"fixed",{"perDose":5,"dosesPerDay":46},2,[48],{"source":34,"section":49},"Dosage and Administration",[51],{"text":52,"refs":55},{"fa":53,"en":54},"صبح و شب؛ پس از بهبود یک بار در روز.","Morning and night; once daily after improvement.",[56],{"source":34,"section":49},[58],{"id":59,"severity":60,"text":61,"refs":64},"ci","block",{"fa":62,"en":63},"حساسیت به اجزا.","Hypersensitivity to any component.",[65],{"source":34,"section":66},"Contraindications",[68],{"text":69,"refs":72},{"fa":70,"en":71},"کودکان نسبت به سرکوب محور HPA و سندرم کوشینگ با کورتون موضعی حساس‌ترند؛ کمترین مقدار مؤثر.","Children are more susceptible to HPA-axis suppression and Cushing's syndrome from topical steroids; use the least effective amount.",[73],{"source":34,"section":74},"Pediatric Use",[],[],[],{"status":79,"reviewer":80,"date":80},"unverified",null,[82],{"regimen":38,"formulation":24,"input":83,"expect":86},{"ageYears":84,"weightKg":85},30,70,{"perDose":5,"perDay":46},[88],"D07AC01",{"status":90,"forms":91,"refs":120},"registered",[92,96,100,104,108,112,116],{"code":93,"en":94,"fa":95},"05476","BETAMETHASONE 0.1% 100G OINT","پماد بتامتازون ۰٫۱ درصد ۱۰۰ گرم",{"code":97,"en":98,"fa":99},"00161","BETAMETHASONE 0.1% 15G CREAM","کرم بتامتازون ۰٫۱ درصد ۱۵ گرم",{"code":101,"en":102,"fa":103},"00160","BETAMETHASONE 0.1% 15G OINT","پماد بتامتازون ۰٫۱ درصد ۱۵ گرم",{"code":105,"en":106,"fa":107},"00159","BETAMETHASONE 0.1% LOTION","لوسیون بتامتازون ۰٫۱ درصد",{"code":109,"en":110,"fa":111},"51913","BETAMETHASONE (AS VALERATE) OINTMENT TOPICAL 0.1 % 500 g","پماد بتامتازون (معادل والرات) ۰٫۱ درصد ۵۰۰ گرم",{"code":113,"en":114,"fa":115},"52657","BETAMETHASONE (AS VALERATE) CREAM TOPICAL 0.1 % 100 g","کرم بتامتازون (معادل والرات) ۰٫۱ درصد ۱۰۰ گرم",{"code":117,"en":118,"fa":119},"52659","BETAMETHASONE (AS VALERATE) OINTMENT TOPICAL 0.1 % 100 g","پماد بتامتازون (معادل والرات) ۰٫۱ درصد ۱۰۰ گرم",[121],{"source":122,"section":123,"url":124},"darooyab-generic","G-4563\u002FBetamethasone-Topical","https:\u002F\u002Fwww.darooyab.ir\u002FG-4563\u002FBetamethasone-Topical",[126,130,134,138,141],{"kind":127,"url":128,"label":129},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=018865","NDA018865",{"kind":131,"url":132,"label":133},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=50d4763d-5a84-4c45-be06-040c4a527470","FDA Betamethasone val.",{"kind":135,"url":136,"label":137},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682799.html","Betamethasone Topical",{"kind":139,"url":140,"label":88},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=D07AC01",{"kind":142,"url":124,"label":143},"darooyab","Betamethasone-Topical",{"lactation":145,"pediatric":154,"pregnancy":162},{"level":146,"text":147,"quote":150,"refs":151},"caution",{"fa":148,"en":149},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.",[152],{"source":34,"section":153},"Precautions\u002FWarnings – Nursing Mothers",{"level":146,"text":155,"quote":158,"refs":159},{"fa":156,"en":157},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.",[160],{"source":34,"section":161},"Precautions\u002FWarnings – Pediatric Use",{"level":146,"quote":163,"text":164,"refs":167},"مصرف در بارداری بتامتازون موضعی گروه C در شرايط خاص و نظارت ويژه پزشك قابل استفاده است:",{"fa":165,"en":166},"دارویاب: گروه C — فقط اگر فایده بیشتر از خطر باشد.","Darooyab: category C — only if benefit outweighs risk.",[168],{"source":122,"section":169,"url":124},"G-4563\u002FBetamethasone-Topical — مصرف در بارداری",{"kind":171,"refs":172,"id":129},"NDA",[173],{"source":34,"section":174},"SPL approval \u002F marketing category",1792191869270]